GlobeNewswire Inc | Aug 26, 2020 08:00AM EDT

August 26, 2020

SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce new data is scheduled to be presented in four poster presentations at the ESMO Virtual Congress 2020 which is being held from 19 to 21 September 2020, Central European Summer Time (CEST).

The new data will be presented from Immuteps phase II TACTI-002 and the investigator-initiated phase I clinical trial, INSIGHT which includes INSIGHT-004. All four poster presentations relate to the Companys lead product candidate, eftilagimod alpha (efti or IMP321). Immutep will announce the data to the market and make the posters available on its website.

ESMO is Europe's most prestigious oncology congress, attracting more than 29,000 industry participants from 137 countries last year. This year it is being held in a virtual format due to COVID-19.

Poster presentations: Initial results from a Phase II study (TACTI-002) ofTitle: eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patientsDate: 17 September 2020, CESTPresenter: Dr Martin Forster, University College London Hospital, London, United Kingdom Initial results from a Phase II study (TACTI-002) ofTitle: eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected 1st line metastatic non-small cell lung carcinomaDate: 17 September 2020, CESTPresenter: Dr Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Safety data from stratum D of the phase I INSIGHT platformTitle: trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entitiesDate: 17 September 2020 CESTPresenter: Dr Thorsten O. Goetze, Krankenhaus Nordwest, University Cancer Center, Frankfurt am Main, Germany The phase I INSIGHT platform trial: Strata A and B evaluatingTitle: feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumorsDate: 17 September 2020 CESTPresenter: Prof Salah-Eddin Al-Batran, Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF)

About TACTI-002

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada). It is evaluating the combination of efti with MSDs KEYTRUDA (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.

About INSIGHT and INSIGHT-004

INSIGHT is a phase I investigator-initiated study being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is evaluating efti as a monotherapy in 12 patients with advanced solid malignancies.

INSIGHT-004 is the fourth arm (stratum D) of the INSIGHT trial and is being conducted under Immuteps collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. It is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab in 12 patients with advanced solid malignancies.

Further information can be found on the Companys website www.immutep.comor by contacting:

Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564;tim@lifesciadvisors.com